From: Circulating cytokines in predicting development of severe acute pancreatitis
All patients (N= 163) | Admission MMS <2 (n= 142) | |||||
---|---|---|---|---|---|---|
Cytokines | Mild or moderately severe AP (n= 138) | P- valueb | Severe (n= 25) | Mild or moderately severe AP (n= 128) | P- valueb | Severe AP (n= 14) |
G-CSF | 119.7 (66.6-198.2) | <0.001 | 260.2 (132.5 to 1011.8) | 118.41 (66.6 to 174.3) | 0.0007 | 234.0 (151.2 to 531.1) |
GRO-α | 58.8 (35.7-92.3) | <0.001 | 128.2 (98.4 to 169.1) | 54.5 (33.2 to 82.5) | 0.002 (NS) | 118.5 (62.4 to 158.4) |
HGF | 1055.5 (764.7-1730.6) | <0.001 | 3613.0 (2055.3 to 6348.8) | 989.6 (753.6 to 1501.6) | <0.001 | 2202.6 (1554.3 to 3305.5) |
IL-2Rα | 214.2 (150.6-316.7) | <0.001 | 483.3 (385.6 to 673.3) | 209.5 (145.5 to 290.4) | 0.0015 (NS) | 449.7 (228.1 to 504.3) |
IL-6 | 59.7 (15.3-202.1) | <0.001 | 428.9 (138.5 to 1796.3) | 49.9 (14.7 to 185.6) | 0.0013 (NS) | 234.5 (66.2 to 1931.3) |
IL-8 | 26.6 (19.3-41.9) | <0.001 | 82.4 (46.4 to 115.6) | 25.41 (18.0 to 37.6) | <0.001 | 59.7 (32.0 to 102.8) |
IL-18 | 139.6 (91.6-187.1) | <0.001 | 202.8 (151.8 to 305.4) | 131.5 (90.7 to 181.5) | 0.062 (NS) | 162.4 (135.3 to 201.6) |
LIFc | 0 (0) | <0.001 | 1 (0 to 1) | 0 (0) | 0.002 (NS) | 1 (0 to 1) |
M-CSF | 14.5 (8.1-28.1) | <0.001 | 40.2 (18.6 to 68.6) | 12.4 (5.5 to 21.5) | 0.007 (NS) | 28.7 (12.2 to 52.0) |
MCP-1 | 49.0 (21.0-111.2) | <0.001 | 125.0 (64.6 to 199.6) | 47.6 (30.0 to 100.6) | 0.032 (NS) | 92.1 (36.3 to 185.2) |
MCP-3 | 17.4 (0.57-53.6) | <0.001 | 54.58 (24.3 to 98.7) | 16.3 (0.2 to 47.9) | 0.006 (NS) | 52.0 (16.5 to 102.1) |
β-NGF | 5.79 (3.65-9.1) | <0.001 | 11.3 (7.4 to 15.9) | 5.5 (3.4 to 8.5) | 0.007 (NS) | 10.4 (4.5 to 15.5) |
SCF | 114.1 (85.2-147.0) | 0.0008 | 155.8 (109.2 to 256.0) | 111.6 (82.0 to 143.3) | 0.012 (NS) | 148.5 (107.3 to 218.9) |
SDF-1α | 87.6 (53.5-151.5) | <0.001 | 163.6 (104.4 to 226.3) | 86.8 (52.8 to 148.5) | 0.010 (NS) | 171.3 (85.1 to 234.8) |